[Eosinophils and antitumour response].

PURPOSE: Immune response probably plays a role in the tumour control. Cytotoxic T-lymphocyte response is antigen-specific and requires previous encounter with the antigen to develop an efficient immune response. Regarding the innate immunity, natural killer (NK) cells can destroy neoplastic cells lacking HLA class I molecules. In addition to these effector cells, eosinophils are granulocytes usually involved in allergic diseases or response to parasitic infections. Many types of cancer, however, are associated with eosinophilia, either in the tumour itself and/or in peripheral blood. We will focus our attention on the putative involvement of eosinophils in the antitumour response. CURRENT KNOWLEDGE AND KEY POINTS: Recent studies on the relationship between tumour and eosinophils have mainly focused on the << tumour-associated tissue eosinophilia >> (TATE), which seems to be more relevant than peripheral blood eosinophilia. Most studies show that TATE is a favourable prognostic marker, except in Hodgkin's disease, since eosinophils probably deliver in this case an antiapoptotic and proliferative signal for Reed-Sternberg cells via the release of soluble CD30L. FUTURE PROSPECTS AND PROJECTS: The putative anti-tumour effect of eosinophils relies on their tight contact with tumour cells. As a consequence, future immunotherapy studies aiming at an anti-tumour eosinophilic reaction might attract and activate eosinophils within the tumour itself. This could be obtained via direct injection of cytokines (IL-3, IL-5, GM-CSF...) at tumour site or by the use of expression vectors encoding for these molecules.